Analytical Data
-
Gene name
F2RL3
- Application
-
Alternative Names
F2RL3; PAR4; Proteinase-activated receptor 4; PAR-4; Coagulation factor II receptor-like 3; Thrombin receptor-like 3
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96RI0
-
Expression Region
18-82aa
-
AA Sequence
GGTQTPSVYDESGSTGGGDDSTPSILPAPRGYPGQVCANDSDTLELPDSSRALLLGWVPTRLVPA
-
Molecular Weight
32.89 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
F2RL3, also known as the protease-activated receptor 4 (PAR4), is a member of the protease-activated receptor family, which plays a crucial role in various physiological processes, including hemostasis, inflammation, and tissue repair. Recent research has focused on understanding the functional implications of F2RL3 in both health and disease states, particularly its involvement in cardiovascular diseases, cancer, and autoimmune disorders. The receptor is activated by coagulation factors, specifically thrombin, which triggers intracellular signaling cascades that modulate cellular responses. Given its significant role in platelet activation and vascular integrity, F2RL3 has emerged as a potential therapeutic target for drug development. Researchers have been particularly interested in the characterizations of its signaling pathways and the development of F2RL3-recombinant proteins to study receptor function and interaction with various ligands. Understanding the structural biology of F2RL3 is essential for elucidating its function and potential roles in pathophysiological conditions. Moreover, engineered recombinant proteins can facilitate high-throughput screening in drug discovery efforts, providing insights into novel inhibitors or modulators of F2RL3 activity. This research is pivotal in expanding our knowledge of G protein-coupled receptors and their contributions to human health, potentially leading to innovative therapeutic strategies in treating related diseases.
